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1. Introduction
Tuberculosis (TB) remains one of the leading causes of death
worldwide. In 2013, an estimated 9 million people developed TB
and 1.5 million died from the disease.1 Despite evidence that TB is
slowly declining, the emergence and spread of multidrug-resistant
strains of Mycobacterium tuberculosis (MDR-TB) represents a major
challenge to the global control of the disease.1,2
High cure rates for susceptible TB can be achieved with
treatment regimens consisting of a 2-month ‘intensive’ phase,
where isoniazid (INH), rifampicin (RIF), pyrazinamide, and
ethambutol are administered, followed by a 4-month ‘continua-
tion’ phase with only INH and RIF.3 However, the effectiveness of
such regimens is threatened by rising resistance to these ﬁrst-line
drugs. In its 2014 report on TB, the World Health Organization
(WHO) estimated that 3.5% of new and 20.5% of previously treated
cases have MDR-TB.1 MDR-TB is caused by M. tuberculosis (M.tb)
isolates resistant to the two most powerful anti-TB drugs, RIF and
INH, and is notoriously difﬁcult to treat, with global success rates of
around 48%.1 The treatment of MDR-TB patients commonly lasts
for 2 years or longer and relies on the use of second-line drugs
(such as ﬂuoroquinolones and injectable aminoglycosides) that are
less effective, more toxic, and far more costly.2 The additional
acquisition of resistance to these second-line drugs deﬁnes
extensively drug-resistant (XDR) cases of TB. The prognosis of
patients infected with XDR-TB is extremely poor,4 and the spread
of these strains raises the possibility of the return to a pre-
antibiotic era.5
The de novo emergence of drug resistance in an individual
patient can occur as a result of low adherence to treatment,
inadequacy of the drug regimen (e.g., wrong antibiotic choices or
dosages, poor drug quality), and patient-dependent pharmacody-
namic and pharmacokinetic properties of the drugs administered.6
In recent years, several determinants of acquired resistance to the
drugs commonly used in the treatment of TB have been elucidated.
These are associated with spontaneous mutations that interfere
with drug–target binding (e.g., for RIF in the rpoB gene, for
ﬂuoroquinolones in the gyrA/B genes), compromise prodrug
activation (e.g., for INH in the katG gene, for PA-824 in the fgd
gene), or cause overexpression of the target (e.g., for INH/
ethionamide in the promoter region of inhA).7 However, the
resistance phenotypes of a signiﬁcant proportion of clinical isolates
of M.tb cannot solely be explained by these mutations: up to 30% of
isolates resistant to INH and approximately 5% of those resistant to
RIF do not harbour mutations in the known resistance genes.8 On
the other hand, there is growing evidence that bacteria are not
merely spectators of their own evolution; instead, they are able to
develop a series of mechanisms that facilitate a rapid adaptation to
changes in their environment (such as exposure to drugs) and
modulate the effects of drug resistance.9–12 These observations
illustrate the complexity of drug resistance in M.tb and highlight
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the need for deeper exploration into the repertoire of strategies
that lead to the emergence and subsequent ﬁxation of drug-
resistant strains of M.tb.
This review outlines recent ﬁndings relating to the evolution and
spread of drug resistance. The aim is not to provide an exhaustive
description of all the mechanisms known to date, but to illustrate
the most important concepts brought to light by recent studies.
2. Identiﬁcation of additional mechanisms of drug resistance
in Mycobacterium tuberculosis
Several approaches have been used to elucidate the molecular
mechanisms employed by bacteria to survive antibiotic treatment.
They include transcriptional studies to proﬁle responses to the
exposure to different drugs, comparative studies of whole genome
sequences of susceptible and resistant strains, and the use of
mutagenesis to study gene function. The application of these
approaches to M.tb has provided us with insights into the modes of
action of current anti-TB drugs and new compounds in the TB drug
discovery pipeline. It has also enabled the identiﬁcation of new
genes and intergenic regions (particularly genes involved in lipid
metabolism, cell wall homeostasis, purine metabolism, and
transcriptional regulation) under positive evolutionary selection
by drug pressure.13–19 However, the role of most of these genes in
drug resistance remains unclear and warrants further study.
Recent efforts have, for example, led to the description of new
mechanisms of resistance to ethambutol. Resistance to this drug
was ﬁrstly attributed to mutations in the embCAB operon
(particularly mutations in codons 306, 406, and 497 of embB),
which encodes for mycobacterial arabinofuranosyltransferases
thought to be the targets of ethambutol.20–22 Subsequently,
Rv3806c and Rv3792 have also been shown to play a role in
ethambutol resistance by increasing the synthesis of decaprenyl-
phosphoryl-b-D-arabinose (a substrate of the EmbCAB enzymes)
and the expression of embC, respectively.23 Some of the mutations
identiﬁed in these genes only conferred low-level resistance to
ethambutol.23 Low-level resistance is deﬁned as an increase in the
minimum inhibitory concentration (MIC) of a particular drug
above that of the average susceptible bacterial population but
below the threshold for clinically relevant resistance.24 The low-
level resistance to ethambutol associated with these mutations
might be a stepping-stone to higher levels of resistance, a view that
is supported by the observation that several ethambutol resistance
mutations can be present in the same resistant isolate.22,23 These
ﬁndings point to a complex pathway to clinical resistance towards
ethambutol: it involves mutations in several genes that are
acquired in a stepwise manner and that interact to determine the
overall level of resistance to this drug.20,21,25 Mutations within the
gidB gene (encoding a putative 16S rRNA methyltransferase) have
similarly been found to produce a low-level streptomycin
resistance phenotype.26 Further work is needed to investigate
the existence of low-level resistance mechanisms against other
anti-TB drugs and determine their clinical signiﬁcance.
3. Contributing factors to the emergence of drug resistance in
Mycobacterium tuberculosis
Exposure to drugs induces a complex stress response in M.tb and
produces changes in metabolic state and activity that functionally
contribute to resistance. The study of such responses, some of which
are discussed below, provides a better understanding of how M.tb
can enhance its ability to survive antibiotic treatment.
3.1. DNA repair system, mutation rates, and antibiotic resistance
There has been increasing interest in the study of the role of
DNA repair systems in the emergence of antibiotic resistance, as
they directly inﬂuence the type and frequency of mutations that
occur in bacteria. Alterations within these systems can result in a
reduced ability to repair DNA damage and, as a consequence,
increase the rates of mutation.27,28 Such mutator phenotypes can
represent a selective advantage under stressful conditions, as
bacteria can more readily develop mutations that will enhance
their survivability (e.g., resistance mutations).27,28
In M.tb, the interest in the study of the link between mutations
within DNA repair genes, hypermutator phenotypes, and an
increased ability to acquire antibiotic resistance was fuelled by the
observation that polymorphisms in three putative antimutator
genes (mut) appeared to be unique to the Beijing lineage.29 Beijing
strains have been associated, in some settings, with a higher risk of
drug resistance (including MDR and XDR) when compared with
that of other lineages.30 Ebrahimi-Rad et al.29 hypothesized that
this higher propensity to acquire resistance could be attributed to
increased mutation rates produced by missense mutations in the
mut genes. Subsequent studies were unable to establish a
deﬁnitive link between particular mutations in such genes and
antibiotic resistance.31 Nonetheless, there is some indication that
the Beijing lineage might be associated with higher mutation
rates.32,33 This seems to be in line with results from whole genome
sequencing that suggest that Beijing isolates are more variable
than non-Beijing ones.34-36 Some of this variability involves genes
encoding DNA repair proteins.37 The implications of these ﬁndings
in the emergence of antibiotic resistance in Beijing strains warrant
further study.
Mutation rates may be raised during exposure to sub-inhibitory
concentrations of certain antibiotics, particularly those whose
primary mode of action is DNA damage.38 For example, ﬂuoroqui-
nolones target DNA gyrase, generating lethal double-stranded DNA
(dsDNA) breaks that induce transcriptional changes in the genes
responsible for DNA repair and preservation of the genome integrity,
such as those involved in the SOS response.39 Genome-wide
expression studies in M.tb have shown the up-regulation of DNA
repair clusters in response to the exposure to ﬂuoroquinolones.40,41
For example, sub-inhibitory concentrations of ciproﬂoxacin induce
the expression of LexA and RecA, the two key regulatory proteins of
the SOS regulon, and of the error-prone DNA polymerase DnaE2
(even though this response is signiﬁcantly delayed after exposure to
the drug).40 In patients with TB infection, the previous use of
quinolones has not only been associated with the development of
resistance to this antibiotic class, but also to ﬁrst-line anti-TB
drugs.42,43 Interestingly, exposure to INH (a drug that does not
directly act on DNA metabolic processes) might also result in the
induction of the SOS response and in higher mutation rates.44,45
SOS-induced DNA polymerases, such as DnaE2, lack intrinsic
proofreading activity, which leads to mutations when DNA
replication bypasses lesions or errors.46 DnaE2 is thought to be
an important mediator of induced mutagenesis (damage-induced
expression of DnaE2 can increase the mutation rate up to 20–50
times) and to play a role in the emergence of drug resistance in
M.tb.47,48 In an in vitro study, resistance to RIF was found to emerge
more frequently in the wild-type than in the dnaE2 knockout
strain.48 Furthermore, speciﬁc RIF resistance-conferring mutations
within the rpoB gene have been associated with the overexpression
of dnaE2 in ﬁtness-impaired strains, suggesting a role for DnaE2 in
the adaptation of these strains.47 A better understanding of this
and other mechanisms of DNA repair in M.tb will allow us to
identify strains with an enhanced ability to adapt and resist
antibiotic treatment.
3.2. Efﬂux pumps—a gateway to high-level resistance?
Many efﬂux pumps of M.tb (belonging to the major facilitator
superfamily, the ATP-binding cassette superfamily, the resistance
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nodulation division family and to the small multidrug resistance
family) have been characterized and their role in antibiotic
resistance investigated. Drug efﬂux pumps are constitutively
expressed in wild-type cells but can be induced by mutations
within their regulatory genes or by the presence of antibiotics (due
to interactions with such regulatory systems).49
The overexpression of several efﬂux systems has been shown in
clinical isolates of MDR-TB upon exposure to common anti-TB
drugs.50,51 In contrast with the high-level resistance caused by
mutations in genes that encode the primary targets of the main TB
drugs, the reduction in intracellular levels of antibiotics caused by
increased activity of efﬂux systems is generally responsible for
only conferring low-level resistance.8,52 The same efﬂux pump can
induce cross-tolerance to structurally and mechanistically diverse
compounds,53,54 and there is a vast overlap in substrate speciﬁcity
among the pumps present in M.tb.55 These ﬁndings, together with
the observation that genes encoding for efﬂux pumps are
overexpressed soon after exposure to drugs, provide evidence to
support the notion that the extrusion of antibiotics mediated by
efﬂux pumps represents a rapid, non-speciﬁc response to highly
noxious agents.52,56 The level of tolerance conferred by these
mechanisms might confer a selective advantage in the presence of
suboptimal, low antibiotic concentrations, enabling the survival of
certain bacterial subpopulations until a classical high-level
mutation emerges and a population with clinically signiﬁcant
antibiotic resistance is established.28,56-58 On the other hand,
individual mechanisms may not be sufﬁcient to confer clinical
resistance but may interact (e.g., additively or synergistically) with
other resistance determinants resulting in high-level resistance.
The differential expression of efﬂux pumps might, at least in part,
explain the observation that some clinical isolates harbouring the
same classical resistance-conferring mutations can have different
antibiotic susceptibility patterns.59
Efﬂux pump inhibitors have been shown to reduce the MICs of a
wide range of drugs (including RIF, INH, ciproﬂoxacin, oﬂoxacin,
streptomycin, and linezolid) in resistant strains of M.tb.52,60-62
Although in vivo data are limited, there is some indication that the
efﬂux pump inhibitor verapamil is able to restore the activity of
RIF, INH, and pyrazinamide against M.tb in mice.53 These ﬁndings
have stimulated an interest in the introduction of inhibitors of
efﬂux pumps into the treatment regimen for TB as an adjunctive
therapy that could increase the intracellular concentration of (and
therefore the susceptibility to) certain drugs, which is particularly
relevant in the treatment of MDR-TB cases. It should be noted that
the exposure of MDR-TB isolates to efﬂux pump inhibitors does not
generally produce a phenotype of full susceptibility, as resistance-
conferring mutations have often accumulated in other genes that
are not inhibited by these agents.63
Efﬂux systems are responsible for fundamental physiological
processes: for example, some of those that have been linked to
antibiotic resistance in M.tb are also involved in virulence,
oxidative stress responses, and growth.64,65 Thus physiological
regulatory systems may determine the levels of drug resis-
tance.63,64 The regulation of these efﬂux systems is still poorly
understood, but several of them have been shown to be induced
during macrophage infection.65,66 In the future, a better under-
standing of the efﬂux substrate speciﬁcities and of the mechanisms
of efﬂux pump regulation will help the development of strategies
to inhibit them.
4. The evolutionary trajectory of drug-resistant Mycobacterium
tuberculosis
Antibiotic resistance mutations represent a selective advantage
during antibiotic treatment, but in vitro studies have shown that
they can signiﬁcantly impair bacterial ﬁtness in the absence of
antibiotics.10,67,68 Interestingly, clinical isolates harbouring such
mutations can be more ﬁt than isogenic laboratory-constructed
strains.69 This observation suggests the existence of other
determinants of ﬁtness that could mitigate the deﬁcits incurred
by resistance mutations. These could be secondary compensatory
mutations or factors related to the genetic background of the
strain.10
Compensatory evolution, by reducing or eliminating the ﬁtness
costs associated with antibiotic resistance, might play a pivotal
role in the spread of drug-resistant M.tb. However, only a few
compensatory mechanisms have been described so far. Sherman
et al.70 showed that INH-resistant strains of M.tb with an
inactivated katG gene can acquire mutations in the regulatory
region of the alkyl hydroperoxide reductase ahpC gene conducive
to its overexpression. The authors concluded that these mutations
might represent a compensatory mechanism for the loss of KatG
catalase–peroxidase activity. In another study, Mycobacterium
smegmatis was used to model the evolution of aminoglycoside
resistance in M.tb.71 It was observed that the ﬁtness cost of an
aminoglycoside resistance-conferring mutation (G1491U) in the
16S rRNA gene, rrs, could be ameliorated by a secondary mutation
within the same gene (C1409A). These dual mutations were
identiﬁed in clinical isolates of M.tb but at low frequencies,
suggesting that their epidemiological relevance might be minor.71
More recently, a set of non-synonymous mutations in the genes
that encode RNA polymerase subunits RpoA and RpoC were
implicated in the compensatory evolution of RIF resistance.72-74
These gene sequences are generally highly conserved in M.tb, so
non-synonymous mutations are likely to represent recently
acquired adaptive mutations and not natural polymorphisms.72
These putative compensatory mutations, which appear to be
preferably located in the rpoA–rpoC interaction region of the rpoC
gene, have been associated with increased in vitro ﬁtness73,75,76
and are often present in MDR-TB strains.72-74 The acquisition of
rpoA-rpoC mutations generally occurs in strains that are already
RIF-resistant due to alterations in the rpoB gene77, in a process that
seems to be facilitated by the continued exposure to drugs.76 This
compensatory evolution leads to improved transmissibility as
evidenced by the clonal expansion of M.tb strains harbouring such
combinations of resistance and compensatory mutations.72,73
Interestingly, these changes are frequently present in strains that
harbour rpoB resistance mutations associated with the lowest in
vitro ﬁtness deﬁcits.72,74 For example, they are often co-present
with rpoB mutation S531L,72 simultaneously one of the most
frequent mutations in RIF-resistant clinical isolates and one of the
least costly.10,68,72,77
In an in vitro study, double drug-resistant mutants of M.
smegmatis containing certain combinations of rpoB and gyrA
mutations (conferring resistance to RIF and oﬂoxacin, respective-
ly) were found to have higher ﬁtness than at least one of the
corresponding single drug-resistant mutants.12 This means that,
in some cases, the overall cost of carrying multiple resistance
mutations can be less than what would be expected if those
mutations had independent (multiplicative) effects on ﬁtness.
Further work is needed to conﬁrm these ﬁndings (as the authors
were unable to exclude the acquisition of compensatory muta-
tions as a possible explanation for the observed phenotypes) and
elucidate the mechanisms behind them. Nonetheless, the
identiﬁcation of the same combinations of rpoB and gyrA
mutations in clinical isolates of M.tb suggests that this might
represent another form of compensatory evolution with a
potential signiﬁcant impact on the emergence of transmissible
MDR-TB strains.78 The acquisition of additional resistance
determinants, instead of further impairing ﬁtness, can ameliorate
the deﬁcits produced by resistance to other drugs. The resulting
strains will have both a selective advantage in the presence of
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antibiotics and increased competitiveness in the absence of such
selective pressure.
The strain genetic background can also modulate in vitro ﬁtness
and drug susceptibility, meaning that the same resistance
mutation can incur different ﬁtness costs and produce different
resistance patterns depending on the host strain. Mutations in the
rpoB, katG, and inhA genes were found to convey different levels of
antibiotic resistance in strains from different phylogenetic lineages
of M.tb.79,80 Furthermore, some resistance mutations appear to be
lineage-speciﬁc,81-83 or more likely to be present in certain M.tb
lineages.69,80,84 There is also an indication that some lineages are
particularly associated with multi-drug resistance85-87 and that
strain background can affect transmissibility.69,80,88,89 On the other
hand, evidence that the genetic background can inﬂuence the
ﬁtness costs of resistance came from the observation that the same
rpoB mutation (H526D) could confer different ﬁtness deﬁcits in
M.tb strains CDC1551 (which belongs to lineage 4) and T85
(lineage 2).69 Further work is needed to elucidate the mechanisms
behind these ﬁndings.
The in vitro studies described above have shed some light on the
interplay between resistance determinants, strain background,
bacterial ﬁtness, and compensatory mutations in the evolution of
antibiotic resistance in M.tb. Less is known about the emergence of
resistance in vivo and the relative importance of each of these
factors. Data from available studies point to the complex evolution
of drug resistance in TB patients undergoing treatment. Within-
host M.tb populations appear to be heterogeneous and highly
dynamic: there are successive changes in antibiotic resistance and
ﬁtness proﬁles of isolates obtained in serial samples from the same
patient.35,36,90,91 The co-existence of subpopulations with different
levels of resistance in the same sample, mixed clonal infections,
and exogenous re-infection, have also been observed.35,36,90-93
MDR is the result of the stepwise accumulation of resistance-
conferring mutations, and highly resistant mutations that do not
impair ﬁtness or transmissibility are favoured in the long-
term.19,35,36,90,91
5. Mathematical modelling—what it can tell us about the
evolution of drug resistance in Mycobacterium tuberculosis
Many of the above outlined mechanisms and aspects of drug
resistance within M.tb are considered in in vitro conditions and in
isolation. Determining how important they are to clinical
populations can be achieved, in part, using mathematical models.
These allow predictions to be made about the impact of such
mechanisms, for example relative ﬁtness,94 on levels of drug
resistance in the future, but can also explore the experimental data
and help in the guidance of new experimental work.9 This becomes
especially important as the pipeline of new drugs for TB treatment
ﬁlls.95 However, it is also useful for understanding the dynamics of
evolution of resistance to the existing spectrum of anti-TB drugs.
The quality of the output from mathematical modelling is
highly dependent on the quality of the data used to construct the
model structure and to inform parameters. Within drug resistance
epidemiology, the data on transmission is relatively poor due to
the current low prevalence and availability of drug susceptibility
tests. These tests are also usually phenotypic and hence may not
capture detailed data on the varying mechanisms or levels of
resistance. Other parameters may be extremely difﬁcult to
measure, such as the relative ﬁtness, or ability to transmit, of
different resistance strains.94 Fortunately, it is likely that
commonly used ﬁtness measures in vitro are matched to clinical
success.10,68 Moreover, mathematical models are hampered by a
desire to accurately capture biological complexity, such as the
many facets of drug resistance mechanisms, without becoming
overly complicated and too difﬁcult to parameterize.
The power of mathematical models to generalize conclusions
from experimental and genetic work, however, means that there
is great scope for collaboration and interaction. Through an
interdisciplinary approach, experimental results can be broad-
ened to applications in the clinical population suffering from TB
disease. Modellers can help to guide experimentalists to collect
needed data, whilst aiding experimentalists to understand the full
impact of their explorations. This is especially true for the
mechanisms outlined in this review – models could be used in the
future to explore both their complex interplay but also to
highlight their potential importance in the spread of drug
resistance within M.tb.
6. Impact for drug development, resistance diagnosis, and
treatment
In light of recent research, the mechanisms and rates of
resistance, as well as the associated ﬁtness costs and compensatory
mutations, should be investigated in the early stages of drug
development, as they provide relevant information about the
potential for the emergence, spread, and ﬁxation of resistance
towards a particular drug. The ideal anti-TB drug would be one for
which resistance mutations are not only rare but also associated
with high ﬁtness costs.96,97 In addition, it is important to identify
targets for which the rate of ﬁtness-restoring mutations is low.
Restoration of ﬁtness will be less likely when the ﬁtness defect is
pleiotropic and affects more than one cellular process.97 The study
of the interactions between mutations conferring resistance to
different antibiotics (namely their combined effect on bacterial
ﬁtness) could help optimize treatment regimens by identifying
those less likely to be associated with the emergence of multiple
drug resistance.
Drug resistance in M.tb is commonly believed to be caused by
single-step mutations, but there is now evidence to suggest that, at
least for certain anti-TB drugs, it is the result of a stepwise
acquisition of mutations leading to a gradual decrease in
susceptibility. The ﬁrst step in this process may involve a mutation
that does not increase the MIC of a drug above the breakpoint for
clinical resistance. These ﬁndings highlight the importance of
unveiling the full spectrum of resistance mechanisms towards a
particular drug. However, low-level resistance is often overlooked
because it is not generally thought to be associated with a higher
likelihood of therapeutic failure. Low-level mutants can, nonethe-
less, be selected in the presence of suboptimal antibiotic
concentrations and serve as a gateway for the ampliﬁcation of
resistance.24,98 TB patients undergoing treatment can be exposed
to such concentrations of anti-TB drugs either as a result of
inadequate dosing (e.g., low patient compliance or poor drug
quality) or gradients of drug concentration created in the body by
the differential penetration of drugs into tissues and lesions.24,99
The identiﬁcation of patients infected with these ‘pre-resistant’
M.tb mutants may suggest the use of increased antibiotic dosages
or an alteration of treatment strategies before the establishment of
full-scale drug resistance.23 However, low-level mutants (such as
those recently described for ethambutol and streptomycin) cannot
be detected by standard culture-based susceptibility testing.
Current methods rely on breakpoint concentrations to qualitative-
ly deﬁne resistance and are, therefore, insensitive to changes in
drug susceptibility below those thresholds. Further studies are
needed to clarify the relationship between the presence of these
low-level mutations, the emergence of clinical resistance, and
patient outcomes to inform potential changes in current diagnostic
tests (e.g., broaden molecular tests for drug resistance to include
screening for such mutations). Given the putative pivotal role of
low-level mutations in the spread of resistance, surveillance
systems based on resistance produced by high-level mutations
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alone may be insufﬁcient. Indeed, high-level resistance mutations
might be just the tip of the iceberg.
Finally, the heterogeneity of within-host M.tb populations can
also have implications for resistance diagnostics. Culture-based
drug susceptibility testing usually involves the examination of a
single isolate from a single sample from a given disease episode,
with the assumption that it is representative of a homogeneous
bacterial population, which might not be the case. Knowing the
existence and prevalence of the different subpopulations and their
corresponding drug susceptibilities could be useful for the
management of the patient. To obtain a measure of the
heterogeneity of the TB infection, several independent bacterial
isolates should to be examined from each patient sample.
Similarly, the heterogeneity of M.tb infections might also confound
molecular antibiotic resistance tests. For example, the GeneXpert
MTB/RIF (Cepheid, Sunnyvale, CA, USA) (which is becoming a
leading screening tool for TB) has an increased false-negative rate
for detecting RIF resistance in mixed M.tb complex infections,
failing to identify it when <90% of the organisms present in the
sample are RIF-resistant. In order to avoid poor clinical outcomes,
GeneXpert results might warrant further conﬁrmation in settings
where mixed infections are common.100
7. Concluding remarks
The mechanisms by which drug resistance emerges and is
ﬁxated in M.tb populations are not wholly understood (Table 1). In
vitro studies have identiﬁed several determinants of resistance to
the main anti-TB drugs, but whole-genome analyses suggest that
the response to drug exposure might be much more complex than
initially thought and involve a set of strategies developed by
mycobacteria to enhance their ability to adapt and evolve.
Furthermore, there are indications that the acquisition of clinically
signiﬁcant resistance to certain drugs might be a stepwise process
that often involves an initial low-level mutation that acts as a
gateway for high-level resistance. The clinical implications of these
ﬁndings should be investigated.
Recent research suggests that bacterial ﬁtness might play a
pivotal role in the spread of antibiotic-resistant M.tb. In vitro,
bacterial ﬁtness is determined by the interplay of numerous factors
including the growth deﬁcits incurred by resistance mutations,
strain genetic background, and compensatory evolution. Future
studies should elucidate the interactions and relative importance
of these and other factors in the transmissibility of drug-resistant
TB. The development of new tools, such as mathematical
modelling, will facilitate this process and provide important
information for the control of drug-resistant TB.
The growing threat of MDR- and XDR-TB highlights the need for
a better understanding of the complexity of drug resistance in
M.tb. This will allow the development of enhanced diagnostic tests
to identify resistant strains and strategies to curb their spread, and
also help the design of more powerful anti-TB drugs.
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